Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | MGNX | Common Stock | Purchase | $1.18M | +200K | +2.34% | $5.88 | 8.73M | Dec 23, 2022 | Direct | |
transaction | MGNX | Common Stock | Purchase | $1.12M | +200K | +2.29% | $5.61 | 8.93M | Dec 27, 2022 | Direct |
Biotech Target N.V. is a wholly-owned subsidiary of BB Biotech AG. Accordingly, BB Biotech AG may be deemed to be the indirect beneficial owner of the securities of MacroGenics, Inc. held directly or indirectly by Biotech Target N.V. This Form 4 is filed jointly by BB Biotech AG and Biotech Target N.V.